159 related articles for article (PubMed ID: 26458590)
1. Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study.
Dodiya HG; Brahmbhatt AP; Khatri PK; Kaushal AM; Vijay DG
J Cancer Res Ther; 2015; 11(3):612-6. PubMed ID: 26458590
[TBL] [Abstract][Full Text] [Related]
2. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: eight-year experience from single centre.
Gupta D; Raina V; Rath GK; Shukla NK; Mohanti BK; Sharma DN
Indian J Cancer; 2011; 48(4):410-4. PubMed ID: 22293253
[TBL] [Abstract][Full Text] [Related]
4. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy?
Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD
Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
9. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy of breast cancer.
Garces CA; Cance WG
Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
Chavez-Macgregor M; Litton J; Chen H; Giordano SH; Hudis CA; Wolff AC; Valero V; Hortobagyi GN; Bondy ML; Gonzalez-Angulo AM
Cancer; 2010 Sep; 116(17):4168-77. PubMed ID: 20564153
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
16. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
18. Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer.
Zhang L; Hao C; Shen X; Hong G; Li H; Zhou X; Liu C; Guo Z
Breast Cancer Res Treat; 2013 Jun; 139(2):361-9. PubMed ID: 23695655
[TBL] [Abstract][Full Text] [Related]
19. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
Wang C; Yuan L; Wu X; Wang Y; Tian H; Zhang G; Wan A; Xiong S; Wang C; Zhou Y; Ma D; Bao Y; Qu M; Jiang J; Zhang Y; Qi X
BMC Med; 2024 Jun; 22(1):252. PubMed ID: 38886794
[TBL] [Abstract][Full Text] [Related]
20. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
